MBX Biosciences, Inc. (MBX)
$49.00-5.81%Close
SELLCRISIS · day 5
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $2.3B
- Beta
- 0.10
- P/E (TTM)
- -20.42
- Short % float
- 21.58%
- Days to cover
- 6.8
- SI change
- +8.2%
- 1W
- -13.91%
- 1M
- -17.63%
- vs SPY 1W
- -13.78%
- vs SPY 1M
- -20.14%
Industry peers
FMP comparable companies · ranked by market cap
- ASNDSELLAscendis Pharma A/S$14.2BRECOVERYQ 35$229.23-1.67%
- RYTMSELLRhythm Pharmaceuticals, Inc.$6.2BBEARQ 20$90.78-3.57%
- VKTXSELLViking Therapeutics, Inc.$3.3BCRISISQ 21$28.51-5.96%
- XERSBUYXeris Biopharma Holdings, Inc.$1.8BBULLQ -1$10.48-2.49%
- KLRASELLKailera Therapeutics, Inc.$1.5BQ -46$11.61-4.94%
- ALTSELLAltimmune, Inc.$508MCRISISQ -5$2.61-5.08%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
ANALYST & RATINGS
LOADING…Loading analyst data…
Company news
FAQ
- What is LOPJLB’s current signal on MBX?
- LOPJLB’s latest quantitative signal on MBX Biosciences, Inc. Common Stock (MBX) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is MBX in?
- MBX Biosciences, Inc. Common Stock (MBX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does MBX Biosciences, Inc. Common Stock (MBX) do?
- MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for in…